Insider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells 11,245 Shares of Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 11,245 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $16.03, for a total value of $180,257.35. Following the sale, the insider now owns 1,085,790 shares in the company, valued at approximately $17,405,213.70. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Day One Biopharmaceuticals Price Performance

NASDAQ DAWN traded up $0.63 during trading hours on Friday, reaching $16.39. 2,315,290 shares of the stock traded hands, compared to its average volume of 954,557. The stock has a 50 day simple moving average of $14.29 and a two-hundred day simple moving average of $14.40. Day One Biopharmaceuticals, Inc. has a 1 year low of $10.90 and a 1 year high of $18.07. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -15.30 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.58. The firm had revenue of $93.76 million for the quarter, compared to analysts’ expectations of $15.05 million. During the same period in the prior year, the business posted ($0.54) earnings per share. On average, sell-side analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in DAWN. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Day One Biopharmaceuticals by 38.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after buying an additional 1,002 shares during the period. ProShare Advisors LLC grew its holdings in shares of Day One Biopharmaceuticals by 9.1% in the first quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock worth $287,000 after purchasing an additional 1,447 shares during the last quarter. SteelPeak Wealth LLC increased its stake in shares of Day One Biopharmaceuticals by 9.8% in the third quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company’s stock worth $242,000 after buying an additional 1,550 shares during the period. Handelsbanken Fonder AB raised its holdings in Day One Biopharmaceuticals by 16.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 27,000 shares of the company’s stock valued at $376,000 after buying an additional 3,900 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. grew its holdings in Day One Biopharmaceuticals by 8.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 64,359 shares of the company’s stock worth $887,000 after acquiring an additional 5,070 shares during the last quarter. Institutional investors own 87.95% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Wedbush reissued an “outperform” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. TD Cowen raised shares of Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday. JPMorgan Chase & Co. dropped their price objective on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $35.71.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.